It is a good question. I can have a go at answering that question later today, I think a 95m Q would be a fantastic outcome, but I have a feeling it may be a little more back ended. I think if we were on-track to hit the midpoint that in itself would be a large vote of confidence given the fact ACAD has been whacked -50% YTD. I suspect the Candian approval whilst a smaller patient population will have an initial increase of new patients that weren't accounted for in the guidance given the priority review means approval "may happen by the end of the year". It would be good if we can book some sales in Canada in this CY.
Acadia, page-621
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |